UT Southwestern Medical Center, Center for Human Nutrition, Dallas, TX.
Department of Radiation Oncology.
Am J Clin Oncol. 2024 Feb 1;47(2):49-55. doi: 10.1097/COC.0000000000001053. Epub 2023 Nov 24.
Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with non-small cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated outcomes.
Using an Institutional Tumor Registry, we evaluated all patients with stages of NSCLC treated at a tertiary care system from 2006 to 2013. We adopted the international consensus definition for cachexia, with staging designated by the registry and positron emission tomography. Radiotherapy delivery and intent were retrospectively assessed.
In total, 1330 patients with NSCLC were analyzed. Curative-intent radiotherapy was utilized equally between patients with cachexia and non-cachexia with stages I to III NSCLC. Conversely, significantly more patients with stage IV disease and cachexia received palliative radiotherapy versus those without (74% vs 63%, P = 0.006). Cachexia-associated survival was unchanged irrespective of tumor-directed radiation therapy with curative or palliative intent. In fact, pretreatment cachexia was associated with reduced survival for patients with stage III NSCLC receiving curative-intent radiotherapy (median survival = 23.9 vs 15.0 mo, P = 0.009). Finally, multivariate analysis identified pretreatment cachexia as an independent variable associated with worsened survival (hazard ratio = 1.31, CI: 1.14,1.52).
Patients with advanced NSCLC with cachexia received more palliative-intent radiation than those without weight loss. Tumor-directed therapy in either a curative or palliative approach failed to alter cachexia patient survival across all stages of the disease. These findings offer critical information on the appropriate utilization of radiation in the management of patients with NSCLC with cachexia.
癌症恶病质是一种非有意的体重减轻导致进行性功能损害的综合征。关于癌症恶病质患者的放射治疗利用的知识有限。我们评估了姑息性和根治性意图的放射治疗在治疗患有恶病质的非小细胞肺癌(NSCLC)患者中的应用,以确定肿瘤定向治疗是否影响与恶病质相关的结局。
我们使用机构肿瘤登记处,评估了 2006 年至 2013 年在三级保健系统治疗的所有 NSCLC 分期患者。我们采用了国际共识定义的恶病质,分期由登记处和正电子发射断层扫描指定。放射治疗的提供和意图是回顾性评估的。
共有 1330 名 NSCLC 患者被分析。在 I 期至 III 期 NSCLC 有恶病质和无恶病质的患者中,根治性放疗的使用率相等。相反,更多患有 IV 期疾病和恶病质的患者接受姑息性放疗而不是没有恶病质的患者(74%对 63%,P = 0.006)。无论肿瘤定向放疗是根治性还是姑息性,与恶病质相关的生存都没有改变。事实上,对于接受根治性放疗的 III 期 NSCLC 患者,治疗前恶病质与降低的生存相关(中位生存=23.9 对 15.0 个月,P = 0.009)。最后,多变量分析确定治疗前恶病质是与生存恶化相关的独立变量(危险比=1.31,CI:1.14,1.52)。
患有晚期 NSCLC 伴恶病质的患者比没有体重减轻的患者接受更多的姑息性放疗。根治性或姑息性肿瘤定向治疗在疾病的所有阶段都未能改变恶病质患者的生存。这些发现提供了关于在管理患有 NSCLC 恶病质的患者时适当利用放射治疗的重要信息。